All News

RheumNow Podcast is Up! Rheum Lives Matter. More about social change, HCQ, JAKs & skin, growing cartilage, FM exercise. Watch it here>https://t.co/LLvADsDJ5O or listen to the Podcast here>https://t.co/pCXzaJUS9s

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is Up! Rheum Lives Matter. More about social change, HCQ, JAKs & skin, growing cartilage, FM exercise. Watch it here>https://t.co/LLvADsDJ5O or listen to the Podcast here>https://t.co/pCXzaJUS9s

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast - The Bad News That's Fit to Print (8.21.20) Dr Jack Cush reviews this week highlights filgotinib rejection, delays in Diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX https://t.co/1oZtU14VOB https://t.co/rcWlbYVKYn

Links:

Dr. John Cush RheumNow ( View Tweet)
podcast logo

RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.

Read Article
To date, the FDA has currently authorized 218 tests under EUAs; these include 176 molecular tests, 39 antibody tests, and 3 antigen tests.

U.S. FDA US_FDA ( View Tweet)

Study of 2 Canadian centers finds amongst 2095 patients taking biologics for #Psoriasis, 23 (1.1%) stopped their biologic for "COVID-19 related concerns". 5/23 restarted biologic for PSO flares. This included TNFi, inhibitors of IL17, IL12/23, IL23 https://t.co/gjSX4P0LMK

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID-19 child case count now over 400,000 https://t.co/bRYvZ5AoYt https://t.co/JhEbvncUbr

Links:

Dr. John Cush RheumNow ( View Tweet)
Preprint analyses of RCTs and 11 nonRCTs showed JAK-inhibitor use in COVID-19 reduced mortality (OR 0.12; 0.03-0.39) & ICU admission (OR 0.05; 0.01-0.26). Similarly Type I interferon Rx also significantly reduced mortality (OR, 0.19; 0.04-0.85, p=0.03) https://t.co/NqKCGzcfwF

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID.virus_.corona.jpg (keep)

Increased Lupus Anticoagulant Activity in COVID-19 Infection

d Jack Cush, MD

JAMA Network Open reports that after adjusting for inflammation, lupus anticoagulant (LA) is significantly increased (positive) in COVID-19 patients and that LA positivity was associated with incidence risk of thrombotic events.

Read Article
Diabetes is a risk factor for COVID mortality; yet Metformin dramatically lowers mortality in a preprint, unreviewed paper - retrospective EHR review of 25,326 subjects COVID tested at UAB; metformin signif reduced mortality risk in DM w/ COVID (OR 0.33) https://t.co/DvZ4b3al1Y

Links:

Dr. John Cush RheumNow ( View Tweet)

NJ study of 764 ICU COVID-19 pts, 210 (27%) received tocilizumab. TCZ treated patients had a lower death rate (49% vs 61%) (HR 0·64, 95% CI 0·47–0·87; p=0·004). Similar results seen in those requiring mechanical vent. or CRP >15 mg/dL https://t.co/idZTDunG1a

Links:

Dr. John Cush RheumNow ( View Tweet)

podcast logo

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20)

d Jack Cush, MD

Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.

Read Article
RheumNow Podcast - The SARS-CoV-2 Update (8-14-20) Dr. Jack Cush highlights the latest numbers on COVID-19 and its impact on Rheumatic Patients. Also, Top 4 best sellers, new take on NR-Ax-SpA & enthesitis https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up: The SARS-CoV-2 Update with info on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors. Watch it here> https://t.co/1WUZQJajgW or podcast listen here>> https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up: The SARS-CoV-2 Update with info on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors. Watch it here> https://t.co/1WUZQJajgW or podcast listen here>> https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in NYC - 46 117 were tested. Overall 13.7% were seropositive. For PCR-positive HCP, 93.5% were also seropositive; PCR-negative HCP 89.7% were also seronegative. https://t.co/ZjzQUK6jmW

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID infection mask

Rheumatic Diseases, Drugs and COVID-19 Guidelines

d Jack Cush, MD

Several recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.

Read Article
3 pts w/ myasthenia gravis occurring after the onset of coronavirus disease 2019 (COVID-19), all were AChR antibody–positive. MG Sxs begain within 5 to 7 days after fever onset. They postulate neurologic damage from COVID may have autoimmune mechanisms https://t.co/YSy0SYoSmL

Links:

Dr. John Cush RheumNow ( View Tweet)

Ann Int Med reports that the use of ACE inhbitors or ARB use is not associated with more severe COVID-19 disease (High-certainty evidence), and these meds are not associated w/ pos. SARS-CoV-2 tests- based on observational studies w/ 23565 COVID-19 adults https://t.co/px0rMH1Pjz

Links:

Dr. John Cush RheumNow ( View Tweet)

covid.corona

Latest COVID-19 Numbers from CDC

d Jack Cush, MD

Following are the latest CDC numbers for COVID-19 in the U.S., including total cases and deaths; the states with the highest number of COVID-19 deaths; and COVID-19 healthcare case numbers.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×